Pharmacokinetic model for Remimazolam in patients undergoing cardiac surgery
Not Applicable
Recruiting
- Conditions
- aortic valve disease
- Registration Number
- JPRN-UMIN000050602
- Lead Sponsor
- Asahikawa Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
BMI >30 kg/m2, BMI <18 kg/m2, pregnant, myasthenia gravis, acute angle closure glaucoma, patients with severe hepatic dysfunction, emergency surgery
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Remimazolam's action in aortic valve disease patients during cardiac surgery?
How does Remimazolam compare to propofol in anesthetic management for cardiac surgery?
What biomarkers are associated with Remimazolam pharmacokinetics in elderly aortic valve disease patients?
What adverse events are reported with Remimazolam use in cardiac surgery and how are they managed?
What are the pharmacokinetic interactions between Remimazolam and beta-blockers in aortic valve disease patients?